Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, CA 94080, USA.
Drug Metab Dispos. 2010 Jan;38(1):133-42. doi: 10.1124/dmd.109.029371.
Flunoxaprofen (FLX) is a chiral nonsteroidal anti-inflammatory drug that was withdrawn from clinical use because of concerns of potential hepatotoxicity. FLX undergoes highly stereoselective chiral inversion mediated through the FLX-S-acyl-CoA thioester (FLX-CoA) in favor of the (R)-(-)-isomer. Acyl-CoA thioester derivatives of acidic drugs are chemically reactive species that are known to transacylate protein nucleophiles and glutathione (GSH). In this study, we investigated the relationship between the stereoselective metabolism of (R)-(-)- and (S)-(+)-FLX to FLX-CoA and the subsequent transacylation of GSH forming FLX-S-acyl-glutathione (FLX-SG) in incubations with rat hepatocytes in suspension. Thus, when hepatocytes (2 million cells/ml) were treated with (R)-(-)- or (S)-(+)-FLX (100 microM), both FLX-CoA and FLX-SG were detected by sensitive liquid chromatography-tandem mass spectrometry techniques. However, these derivatives were observed primarily from (R)-(-)-FLX incubation extracts, for which the formation rates of FLX-CoA and FLX-SG were rapid, reaching maximum concentrations of 42 and 2.8 nM, respectively, after 6 min of incubation. Incubations with (S)-(+)-FLX over 60 min displayed 8.1 and 2.7% as much FLX-CoA and FLX-SG area under the concentration versus time curves, respectively, compared with corresponding incubations with (R)-(-)-FLX. Coincubation of lauric acid (1000 microM) with (R)-(-)-FLX (10 microM) led to the complete inhibition of FLX-CoA formation and a 98% inhibition of FLX-SG formation. Reaction of authentic (R,S)-FLX-CoA (2 microM) with GSH (10 mM) in buffer (pH 7.4, 37 degrees C) showed the quantitative formation of FLX-SG after 3 h of incubation. Together, these results demonstrate the stereoselective transacylation of GSH in hepatocyte incubations containing (R)-(-)-FLX, which is consistent with bioactivation by stereoselective (R)-FLX-CoA formation.
氟比洛芬(FLX)是一种手性非甾体抗炎药,由于潜在的肝毒性问题,已退出临床使用。FLX 通过 FLX-S-酰基辅酶 A 硫酯(FLX-CoA)介导的高度立体选择性手性反转,有利于(R)-(-)-异构体。酸性药物的酰基辅酶 A 硫酯衍生物是化学活性物质,已知可转移蛋白亲核试剂和谷胱甘肽(GSH)。在这项研究中,我们研究了(R)-(-)-和(S)-(+)-FLX 立体选择性代谢为 FLX-CoA 以及随后与 GSH 发生转酰基反应形成 FLX-S-酰基-谷胱甘肽(FLX-SG)之间的关系,在悬浮大鼠肝细胞孵育中。因此,当肝细胞(200 万个细胞/ml)用(R)-(-)-或(S)-(+)-FLX(100 microM)处理时,通过灵敏的液相色谱-串联质谱技术检测到 FLX-CoA 和 FLX-SG。然而,这些衍生物主要从(R)-(-)-FLX 孵育提取物中观察到,其中 FLX-CoA 和 FLX-SG 的形成速率很快,在孵育 6 分钟后分别达到 42 和 2.8 nM 的最大浓度。与(R)-(-)-FLX 孵育相比,(S)-(+)-FLX 孵育 60 分钟显示 FLX-CoA 和 FLX-SG 的面积分别为 8.1%和 2.7%。用 1000 microM 月桂酸与 10 microM(R)-(-)-FLX 共孵育完全抑制了 FLX-CoA 的形成,并抑制了 98%的 FLX-SG 形成。在缓冲液(pH 7.4,37 摄氏度)中用 2 microM 真实(R,S)-FLX-CoA 与 GSH(10 mM)反应 3 小时后,定量形成了 FLX-SG。综上所述,这些结果表明在含有(R)-(-)-FLX 的肝细胞孵育中 GSH 的立体选择性转移酰基,这与立体选择性(R)-FLX-CoA 形成的生物活化一致。